This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →
Roche outlays $2.3bn for Hanmi's non-GLP-1 obesity candidate
The licensing deal marks a diversification of Roche's obesity pipeline as it seeks entry into the lucrative market.
By Pharmaceutical Technology
· Aug 24, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Cytokinetics' cardiac myosin inhibitor, Myqorzo, is the first to demonstrate significant, clinically meaningfu…
The WeekFierceBiotech ↗
Roche's Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) desig…
The WeekSTAT News ↗
It took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second coul…